Gefitinib with chemotherapy does not significantly improve progression-free survival in gefitinib-resistant lung cancer versus chemotherapy alone

At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation of gefitinib with chemotherapy versus chemotherapy alone provided no significant improvement in progression-free survival in patients with EGFR mutation-positive lung cancer who previously failed to respond to first-line gefitinib.